Health Care & Life Sciences » Biotechnology | ARCA biopharma Inc.

ARCA biopharma Inc. | Mutual Funds

Mutual Funds that own ARCA biopharma Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
FTIF SICAV - Franklin Biotechnology Discovery Fund
2,068,536
14.87%
0
0.06%
06/30/2018
Tekla Life Sciences Investors
811,227
5.83%
0
0.1%
12/31/2017
Fidelity Spartan Extended Market Index Fund
48,679
0.35%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
38,180
0.27%
0
0%
07/31/2018
FCP OP Medical [email protected]
38,000
0.27%
0
0.01%
11/30/2017
Pharma/wHealth Fund
8,100
0.06%
0
0%
11/30/2017
RIM Global - CC Bioscience
3,500
0.03%
0
0.02%
06/30/2017
3,431
0.03%
0
0.01%
09/05/2018
Vanguard Invt. Fds. ICVC - US Equity Index Fund
2,000
0.01%
0
0%
06/30/2018
iShares Core S&P Total US Stock Market ETF
865
0.01%
0
0%
09/06/2018

About ARCA biopharma

View Profile
Address
11080 CirclePoint Road
Westminster Colorado 80020
United States
Employees -
Website http://www.arcabiopharma.com
Updated 07/08/2019
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications.